Esperion Therapeutics Inc.'s oral, once-daily bempedoic acid delivered its first set of positive Phase III results for LDL cholesterol reduction, in a trial done in statin intolerant patients,though there still are questions about how the drug would be received by payers if it does ultimately get to the market.
Esperion plans to report results this year from all five pivotal studies in the Phase III CLEAR development program for...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
